

Thiago Vidotto, MSc, PhD

xxxxxxx@gmail.com | +55xxxxxxxxx

EDUCATION

Post-doctoral fellow in Pathology (June 2019 – July 2020)

- Johns Hopkins Hospital, Baltimore, USA.

PhD in Genetics (September 2015 – March 2019)

- University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
- Queen's University, Kingston, Canada (Sandwich PhD for 8 months)

MSc in Psychobiology (January 2013 - September 2015)

- University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

Specialist in Astrobiology (January 2012 - January 2013)

- State University of Londrina, Londrina, Paraná, Brazil.

BSc in Life Sciences (January 2009 - January 2012)

- State University of Londrina, Londrina, Paraná, Brazil.

RESEARCH EXPERIENCE

Post-doctoral fellow – Department of Pathology, Johns Hopkins Hospital, Baltimore, USA

- Analyzed and integrated genomic methylation data from prostate tumors.
- Integrated gene expression, mutational, and methylation data using clustering algorithms.
- Obtained copy number data from whole genome methylation data of prostate cancer samples.
- Validated copy number platforms using immunohistochemistry and FISH techniques.
- Measured the impact of genomic alterations in the immune response from Black and White patients with prostate cancer.
- Generated immune-cell density data from methylation and gene expression platforms.
- Validated Gleason Score classification algorithms build upon Artificial Intelligence.
- Analysed RNAseq data from tumor samples and cell lines to identify differentially expressed genes and enriched pathways.
- Obtained percent genome altered and other genomic parameters from methylation data.

PhD Sandwich– Department of Biomedical and Molecular Sciences, Cancer Research Institute, Queen's University, Kingston, Canada

- Analysed RNAseq, WGS and WES from public domain and Canadian consortium databases.
- Employed bioinformatics tools to evidence the association between mutations in bladder tumors and the tumor microenvironment changes.
- Analysed the effect of mutations and genomic rearrangements on the expression of immune-cell markers and activators.
- Experience in bioinformatics and biostatistics using R programming language.

PhD in Genetics – University of São Paulo, Medical School of Ribeirão Preto, São Paulo, Brazil

- Compared prostate cancer patient outcome with and without common genomic alterations using statistical models.
- Integrated pathological and genomic data obtained from immunohistochemistry, arrayCGH, sequencing, and FISH.

- Employed bioinformatics and statistical tools to elucidate the mechanisms of inactivation of PTEN and its impacts in the genome and immune response of prostate cancer.

PUBLICATIONS IN PEER-REVIEWED JOURNALS

WEINER, A B; **VIDOTTO, T** et al. Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. **Nature Communications**, v. 12, p. 935, 2021.

CHENARD, S; JACKSON, C; **VIDOTTO, T** et al. Sexual Dimorphism in Outcomes of Non-muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint. **European Urology Open Science**, v. 29, p. 50-58, 2021.

ASRANI, K; TORRES, A F C; WOO, J; **VIDOTTO, T** et al. Reciprocal YAP1 loss and expression in neuroendocrine prostate cancer. **Journal of Pathology**, in press, 2021.

IMADA, E L; SANCHEZ, D F; DINALANKARA, W; **VIDOTTO, T** et al. Transcriptional landscape of PTEN loss in primary prostate cancer. **BMC Cancer**, v. 21, p. 856-864, 2021.

SALLES, D C; **VIDOTTO, T** et al. Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies. **Journal of Molecular Diagnostics**, v. 23, p. 1030-1041, 2021.

JAMASPISHVILI, T; PATEL, P G; NIU, Y; **VIDOTTO, T** et al. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN). **Journal of the National Cancer Institute**, v. 112, p. 1098-1104, 2020.

VIDOTTO, T et al. Emerging role of PTEN loss in evasion of the immune response to tumours. **British Journal of Cancer**, v. 122, p. 1732-1743, 2020.

HARMON, S A; PATEL, P G; SANFORD, T H.; CAVEN, I; ISEMAN, R; **VIDOTTO, T** et al. High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts. **Modern Pathology**, v. 34, p. 478-489, 2020.

VIDOTTO, T. et al. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. **The Prostate**, v. 79, p. 969-979, 2019.

VIDOTTO, T. et al. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes. **Journal for Immunotherapy of Cancer**, v. 7, p. 148-156, 2019.

VIDOTTO, T et al. Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer. **Molecular Cytogenetics**, v. 11, p. 1-9, 2018.

And 10 more publications in high-impact journals in the field of oncology, pathology, and bioinformatics.

LANGUAGE

English (fluent), Spanish (basic), Portuguese (native speaker).